Ciclo celular / Checkpoint
Los inhibidores del ciclo celular/puntos de control son compuestos que interrumpen la progresión normal del ciclo celular, particularmente en puntos de control regulatorios clave. Estos inhibidores son cruciales para estudiar la división celular, comprender la proliferación de células cancerosas y desarrollar terapias anticancerígenas. Al dirigirse a fases específicas del ciclo celular, estos inhibidores pueden inducir la detención del ciclo celular, lo que lleva a apoptosis o senescencia en células de división rápida. En CymitQuimica, ofrecemos una amplia gama de inhibidores de alta calidad del ciclo celular/puntos de control para apoyar su investigación en biología del cáncer, biología celular y desarrollo de fármacos.
Subcategorías de "Ciclo celular / Checkpoint"
- Aurora quinasa(114 productos)
- CDK(546 productos)
- Detención del ciclo celular(5 productos)
- Chk(48 productos)
- DYRK(47 productos)
- Dynamin(27 productos)
- Ferroptosis(226 productos)
- HSP(179 productos)
- Integrin(251 productos)
- Kinesina(87 productos)
- LIM quinasa(20 productos)
- Asociado a microtúbulos(274 productos)
- PKC(124 productos)
- PLK(25 productos)
- ROCK(62 productos)
- Rho(6 productos)
- Wee1(14 productos)
- c-Myc(76 productos)
Mostrar 10 subcategorías más
Se han encontrado 3870 productos de "Ciclo celular / Checkpoint"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PARG-IN-7
CAS:PARG-IN-7 (Example 38) is a Poly ADP-ribose glycohydrolase (PARG) inhibitor with an IC50 of less than 0.1 μM. It reduces the viability of HCC1806-XRCC1 knockdown (KD) cells, exhibiting an IC50 of less than 1 μM. PARG-IN-7 is applicable in cancer research.Fórmula:C22H24F2N8O3S2Forma y color:SolidPeso molecular:550.61Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Fórmula:C20H22F2N4O2SForma y color:SolidPeso molecular:420.48DB18
CAS:DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].Fórmula:C24H18ClN7O3Forma y color:SolidPeso molecular:487.93'-NH2-CTP
CAS:3'-NH2-CTP is a nucleotide analog modified with an amino group at the 3' position of CTP.Fórmula:C9H17N4O13P3Forma y color:SolidPeso molecular:482.17Eprociclovir Na
CAS:Eprociclovir Na (A-5021) is 15x stronger than acyclovir at inhibiting herpesviruses, showing promise for EHV1 and herpetic keratitis treatment.Fórmula:C11H14N5NaO3Forma y color:SolidPeso molecular:287.25Glycyl H-1152 hydrochloride
CAS:Glycyl-H-1152 is a potent ROCK-II inhibitor (IC50=11.8 nM) with high selectivity over CaMKII, PKG, Aurora A, PKA, and PKC. Better than Y-27632 and HA-1077.Fórmula:C18H26Cl2N4O3SForma y color:SolidPeso molecular:449.39MY05
CAS:MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).Fórmula:C19H11ClN4OForma y color:SolidPeso molecular:346.77Haspin-IN-2
CAS:Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).Fórmula:C12H8N4O3Forma y color:SolidPeso molecular:256.22isoGTP lithium
CAS:isoGTP (Isoguanosine-5'-triphosphate) lithium is a GTP analog.Fórmula:C10H12Li4N5O14P3Forma y color:SolidPeso molecular:546.91α5β1 integrin agonist-1
CAS:α5β1 integrin agonist-1 is an α5β1 integrin agonist that selectively delivers 5-FU to tumour cells and induces tumour cell death.Fórmula:C24H26FN5O9Forma y color:SolidPeso molecular:547.49Zalunfiban dihydrochloride
Zalunfiban (RUC-4) is a potent αIIbβ3 platelet antagonist, IC50 45 nM, used in myocardial infarction research.Fórmula:C16H20Cl2N8O2SForma y color:SolidPeso molecular:459.358-Azakinetin riboside
CAS:8-Azakinetin riboside, a structural analog of kinetin riboside, exhibits cytotoxic activity [1].Fórmula:C14H16N6O5Forma y color:SolidPeso molecular:348.31Aurora/LIM kinase-IN-1
Aurora/LIM kinase-IN-1 (Compound F114) is a dual inhibitor targeting aurora and lim kinases, potentially useful in GBM cancer treatment efforts.Fórmula:C16H20N6OForma y color:SolidPeso molecular:312.37Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Fórmula:C19H21N5O2Forma y color:SolidPeso molecular:351.40MtTMPK-IN-7
MtTMPK-IN-7 inhibits MtbTMPK (IC50: 47 μM), active against M. brevis (MIC: 2.3-4.7 μM), useful for tuberculosis research.Fórmula:C27H29ClN6O3Forma y color:SolidPeso molecular:521.01BRD-7880
CAS:BRD-7880 is a potent and highly specific inhibitor of aurora kinases B and C.Fórmula:C32H38N4O7Forma y color:SolidPeso molecular:590.67Aurora B inhibitor 1
CAS:Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 uM) with potential anticancer activity for cancer research.Fórmula:C25H26ClF2N7O2Pureza:98.37%Forma y color:SolidPeso molecular:529.97DIDS
CAS:DIDS inhibits anion exchangers reversibly then irreversibly and blocks RAD51.Fórmula:C16H10N2O6S4Pureza:98%Forma y color:SolidPeso molecular:454.52Dyrk1A/B-IN-1
Dyrk1A/B-IN-1 (3n) is a potent DYRK1A/B inhibitor, cell-permeable, with Ki values of 67.8 nM (1A) and 237.9 nM (1B), IC50s of 1.1 and 0.8 μM.Fórmula:C21H17N3O2S2Forma y color:SolidPeso molecular:407.51PKMYT1-IN-2
CAS:PKMYT1-IN-2 (compound 2) serves as a powerful inhibitor of PKMYT1, exhibiting an IC 50 of 5.7 nM. Additionally, it effectively suppresses the proliferation of HCC1569 cells with an IC 50 of 22 nM [1].Fórmula:C22H19N5O2Forma y color:SolidPeso molecular:385.42Sovesudil hydrochloride
Sovesudil (PHP-201) HCl: potent local ROCK inhibitor; targets ROCK I/II (IC50: 3.7/2.3 nM); lowers IOP, non-congesting.Fórmula:C23H23ClFN3O3Forma y color:SolidPeso molecular:443.96-N-Hydroxylaminopurine
CAS:6-N-Hydroxylaminopurine is a base analog with mutagenic activity.Fórmula:C5H5N5OPeso molecular:151.13RNase L ligand 3
CAS:RNase L ligand 3 is an RNase L ligand employed in the synthesis of F3-PEG8-RiboTAC.Fórmula:C27H27N3OSForma y color:SolidPeso molecular:441.59L-I-OddU
CAS:L-I-OddU: Selective anti-EBV, halts virus DNA/protein synthesis. EC50: 0.03 µM, low toxicity (CC50: 1000 nM).Fórmula:C8H9IN2O5Forma y color:SolidPeso molecular:340.07LNA-GDP
CAS:LNA-GDP is a nucleotide analog utilized in the synthesis of oligonucleotides.Fórmula:C11H15N5O11P2Forma y color:SolidPeso molecular:455.21CB 30900
CAS:CB30900 is a novel and effective thymidylate synthase inhibitor.Fórmula:C31H32FN5O9Forma y color:SolidPeso molecular:637.61AGH-107
CAS:AGH-107 is a highly selective 5-HT7 receptor agonist that can cross the blood-brain barrier, featuring a Ki value of 6 nM and an EC50 value of 19 nM. Demonstrating high selectivity for central nervous system targets, AGH-107 also exhibits high metabolic stability and low toxicity in HEK-293 and HepG2 cell cultures.Fórmula:C13H12IN3Forma y color:SolidPeso molecular:337.16CDK9 autophagic degrader 1
CAS:CDK9 autophagic degrader 1 (Compound 28) is an ATTEC degrader used to target and degrade CDK9, also impacting the levels of its associated Cyclin T1. At a concentration of 100 nM, it exhibits over 80% inhibition of CDK9.Fórmula:C34H39N7O4S2Forma y color:SolidPeso molecular:673.8485'-DMT-5-F-2'-dU Phosphoramidite
CAS:5'-DMT-5-F-2'-dU Phosphoramidite is a nucleoside phosphoramidite analog employed in oligonucleotide synthesis. It plays a crucial role in developing therapeutic oligonucleotides, which are used in crafting drugs for cancer treatment.Fórmula:C39H46FN4O8PForma y color:SolidPeso molecular:748.7773′-Amino-2′,3′-dideoxy-CTP
CAS:3′-Amino-2′,3′-dideoxy-CTP is an analog of nucleoside triphosphates. It selectively inhibits DNA polymerase β.Fórmula:C9H17N4O12P3Forma y color:SolidPeso molecular:466.17SF0166
CAS:SF0166: potent αvβ3 antagonist, IC50: 0.6 nM. Blocks cell adhesion, IC50: 7.6 pM-76 nM. Reduces neovascularization in mice.Fórmula:C23H27F2N5O4Forma y color:SolidPeso molecular:475.49CDK7-IN-17
CAS:CDK7-IN-17 (compound 11) is a pyrimidine-derived CDK7 inhibitor for studying transcription-disrupted cancers.Fórmula:C24H26F3N6OPPureza:99.60%Forma y color:SolidPeso molecular:502.47USP7-IN-10
CAS:USP7-IN-10 is a potent inhibitor of ubiquitin-specific protease 7 (USP7), exhibiting an inhibition concentration half-maximal (IC50) value of 13.39 nM.Fórmula:C26H29ClN4O3SForma y color:SolidPeso molecular:513.05CDK7/12-IN-1
CAS:CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.Fórmula:C25H34N8OForma y color:SolidPeso molecular:462.59Kolavenic acid analog
CAS:KAA, an anticancer compound, inhibits centrosome clustering and targets HSET+ yeast and cancer cells.Fórmula:C25H38O4Forma y color:SolidPeso molecular:402.572'-(2-Nitrobenzyl)-ATP
CAS:2'-(2-Nitrobenzyl)-ATP is an analog of rATP. It acts as a transcription terminator by inhibiting the elongation of RNA chains by T7 RNA polymerase.Fórmula:C17H21N6O15P3Forma y color:SolidPeso molecular:642.30DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Fórmula:C18H26N4O3SForma y color:SoildPeso molecular:378.49TA-316
CAS:Agent induces megakaryocytes/platelets from stem cells to treat thrombopenia.Fórmula:C28H25BrN4O5S2Pureza:98%Forma y color:SolidPeso molecular:641.56Ladirubicin
CAS:Ladirubicin, as an anthracyclines analog is the leading compound of alkylcyclines.Fórmula:C29H31NO11SForma y color:SolidPeso molecular:601.62CBP/p300-IN-2
CAS:CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).Fórmula:C27H29F2N7O2Pureza:98%Forma y color:SolidPeso molecular:521.56CDK9-IN-11
CAS:CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].Fórmula:C20H25N3O4Pureza:98%Forma y color:SolidPeso molecular:371.43MRL-436
CAS:MRL-436 is an RNA polymerase inhibitor with antibacterial activity. Its effectiveness depends on the β' subunit and the 622nd residue of the RNAP ω subunit. MRL-436 can inhibit Rifampicin-resistant RNA polymerase derivatives and shows antibacterial activity against Rifampicin-resistant strains.Fórmula:C24H22N4OForma y color:SolidPeso molecular:382.463'-NH-Tr-2',3'-DMF-ddA-5'-CE-Phosphoramidite
CAS:3'-NH-Tr-2',3'-DMF-ddA-5'-CE-Phosphoramidite serves as a precursor of adenosine nucleotide monomers used in the solid-phase synthesis of oligonucleotides, particularly for modifying oligonucleotides such as terminally modified DNA strands. It features Trityl (Tr), Cyanoethyl (CE), and Dimethylformamidine (DMF) protective groups, classifying it as a ddNTP adenosine nucleoside suitable for applications like oligonucleotide solid-phase synthesis, probe design, and chain termination sequencing.Fórmula:C41H50N9O3PForma y color:SolidPeso molecular:747.87USP7-797
CAS:USP7-797 is a selective non-covalent active site USP7 inhibitor, inhibiting USP7 and ubiquitin binding, with anti-tumor, oral and high efficiency properties.Fórmula:C27H28ClN3O3SPureza:95.90% - 95.90%Forma y color:SolidPeso molecular:510.052′-OMe-UDP
CAS:2′-OMe-UDP is a nucleotide analog utilized in the synthesis of oligonucleotides.Fórmula:C10H16N2O12P2Forma y color:SolidPeso molecular:418.19Xanthosine-5'-Triphosphate trisodium
CAS:Xanthosine-5'-Triphosphate (5'-XTP) trisodium is a nucleotide formed through the deamination of purine bases. It serves as a substrate for inosine triphosphate pyrophosphatase (ITPase).Fórmula:C10H12N4Na3O15P3Forma y color:SolidPeso molecular:590.111Aurora A inhibitor 1
CAS:Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)Fórmula:C25H28ClF2N5O2Forma y color:SolidPeso molecular:503.97Werner syndrome RecQ helicase-IN-2
CAS:Werner syndrome RecQ helicase-IN-2 is a potent Werner syndrome RecQ DNA helicase (WRN) inhibitor, useful in research on colorectal and gastric cancers.Fórmula:C32H34F3N9O5Pureza:99.02%Forma y color:SolidPeso molecular:681.67Cimpuciclib tosylate
CAS:Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.Fórmula:C37H43FN8O4SForma y color:SolidPeso molecular:714.85Mitotic kinesin-IN-1 hydrochloride
CAS:Mitotic kinesin-IN-1 hydrochloride (Example 80) is an inhibitor of mitotic kinesin, which suppresses cell proliferation by hindering mitosis. This compound is applicable in research related to cancer, cardiac hypertrophy, immune and inflammatory diseases, and fungal infections.Fórmula:C22H26ClF2N3OSForma y color:SolidPeso molecular:453.98WRN inhibitor 13
CAS:WRN inhibitor 13 is an inhibitor of the WRN helicase with a pIC50 value ranging from 6 to 7.Fórmula:C16H20N2O5SForma y color:SolidPeso molecular:352.40514α-Demethylase/DNA Gyrase-IN-1
14α-Demethylase/DNA Gyrase-IN-1 (Compound 7c) is a potent inhibitor of 14α-Demethylase/DNA Gyrase with antibacterial activity.Fórmula:C26H22N4O4Forma y color:SolidPeso molecular:454.48Zorubicin
CAS:Zorubicin, a Daunorubicin derivative, targets topoisomerase II, inhibits DNA polymerase, and researches acute leukemia, sarcomas.Fórmula:C34H35N3O10Forma y color:SolidPeso molecular:645.66Valopicitabine
CAS:Valopicitabine is an effective prodrug of the effective anti-HCV drug 2'-C-methylcytidine and can be used as a promising antiviral drug for the study of chronicFórmula:C15H24N4O6Pureza:98%Forma y color:SolidPeso molecular:356.37CDK2-IN-18
CAS:CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].Fórmula:C21H23N7O2SForma y color:SolidPeso molecular:437.52GHP-88309
CAS:GHP-88309 is an orally active, broad-spectrum anti-paramyxovirus agent that targets viral polymerase, interrupting viral RNA synthesis. It effectively inhibits respiratory syncytial virus (RSV), measles virus (MeV), and canine distemper virus (CDV) with an EC50 of 0.06-1.2 μM. In mouse models, GHP-88309 demonstrates significant anti-infective activity.Fórmula:C16H11FN2OForma y color:SolidPeso molecular:266.27PARG-IN-6
CAS:PARG-IN-6 (Compound 2) is an orally bioavailable PARG inhibitor with an IC50 of 0.3 nM. It exhibits significant anticancer activity against cancer cells, with an IC50 of 0.0368 μM for HCC1395 cells. PARG-IN-6 shows potential for research in colon cancer, appendiceal cancer, and pancreatic cancer.Fórmula:C24H25F4N7O4S3Forma y color:SolidPeso molecular:647.69L-2'-Fd4C
CAS:L-2'-Fd4C is an L-nucleoside analogue with both anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity [1].Fórmula:C9H10FN3O3Forma y color:SolidPeso molecular:227.19DHICA
CAS:DHICA (5,6-Dihydroxyindole-2-carboxylic acid) is an intermediate in melanin synthesis and a component of eumelanin, as well as acting as a moderate potency agonist of GPR35. In the U2OS cell line, DHICA demonstrates the ability to induce β-arrestin translocation signaling with an EC50 value of 23.2 μM. Additionally, it plays a significant role in promoting and protecting against DNA damage.Fórmula:C9H7NO4Forma y color:SolidPeso molecular:193.16Pol I-IN-1
Pol I-IN-1 is a powerful inhibitor of RNA polymerase I (Pol I), specifically targeting the large catalytic subunit RPA194, demonstrating an inhibitionFórmula:C23H22N4O2Forma y color:SolidPeso molecular:386.45D-G23
CAS:D-G23 is a selective RAD52 inhibitor. It disrupts RAD52-mediated DNA repair pathways and suppresses the growth of cancer cells deficient in BRCA1 and BRCA2. D-G23 shows promise for research into homologous recombination-related cancers caused by BRCA1/2 mutations, such as hereditary breast and ovarian cancers.Fórmula:C19H22N4O3Forma y color:SolidPeso molecular:354.403Antifolate agent 1
CAS:Antifolateagent 1 (Compound 1) is an antifolate agent featuring a single-carbon bridge. It lacks RFC transport, shows no affinity for FRα and FRβ, and exhibits no GARFTase inhibition activity. Antifolateagent 1 serves as a negative control in the development of folate receptor-targeted antifolate agents.Fórmula:C19H19N5O6Forma y color:SolidPeso molecular:413.383'-NH-Tr-2',3'-ddG(iBu)-5'-CE-Phosphoramidite
CAS:3'-NH-Tr-2',3'-ddG(iBu)-5'-CE-Phosphoramidite is a nucleoside phosphoramidite monomer featuring protective group modifications, suitable for RNA oligonucleotide synthesis.Fórmula:C42H51N8O5PForma y color:SolidPeso molecular:778.88Deoxythymidine-5'-triphosphate-d15
CAS:Deoxythymidine-5'-triphosphate-d15 (dTTP-d15) dilithium is a deuterium-labeled form of deoxythymidine-5'-triphosphate. Deoxythymidine-5'-triphosphate (dTTP) is a triphosphate nucleotide utilized in DNA synthesis.Fórmula:C10H15Li2N2O14P3Forma y color:SolidPeso molecular:509.13Antibacterial agent 110
Compound 4e, an antibacterial against P. aeruginosa, disrupts cell membranes (MIC: 1 μg/ml).Fórmula:C22H21N5O4SForma y color:SolidPeso molecular:451.5DENV-IN-6
CAS:DENV-IN-6, a potent anti-DENV (I-IV) and HIV-1 IIIB inhibitor with EC50 ranging 6.8-17.5 μM for DENV and EC50 0.0181 μM for HIV-1.Fórmula:C23H26ClFN4OSForma y color:SolidPeso molecular:461Plevitrexed
CAS:Plevitrexed, an oral TS inhibitor (Ki: 0.44 nM), targets α-folate receptor & reduced folate carrier, treats gastric cancer.Fórmula:C26H25FN8O4Pureza:98%Forma y color:SolidPeso molecular:532.53LNA-CTP
CAS:LNA-CTP is a nucleotide analog utilized in the synthesis of oligonucleotides.
Fórmula:C10H16N3O14P3Forma y color:SolidPeso molecular:495.17Rhodblock 1a
CAS:Rhodblock 1a is an inhibitor of the Rho kinase signaling pathway, which disrupts the localization and function of proteins within the Rho pathway. This interference hinders the proper formation of the cleavage furrow during cell division, leading to some cells either failing to form the cleavage furrow or forming a ruptured furrow, resulting in binucleated cells. Rhodblock 1a can be utilized for investigating cell division mechanisms and holds potential for research into cardiovascular diseases and cancer.
Fórmula:C20H16N2O2Forma y color:SolidPeso molecular:316.353Tripolin B
CAS:Tripolin B is an ATP-competitive inhibitor of Aurora kinases, with IC50 values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. However, it exhibits no inhibitory effect within cells.Fórmula:C12H9N3OPeso molecular:211.22Anticancer agent 29
Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).Fórmula:C22H15ClFNOForma y color:SolidPeso molecular:363.812′-O-MOE-CMP
CAS:2′-O-MOE-CMP is a nucleotide analogue utilized in the synthesis of oligonucleotides.Fórmula:C12H20N3O9PForma y color:SolidPeso molecular:381.28IRE1α kinase-IN-5
IRE1α kinase-IN-5 (compound 7) is a potent inhibitor of IRE1α (Ki: 98 nM) and is an ATP-competitive ligand for IRE1α.Fórmula:C28H30N6O3SForma y color:SolidPeso molecular:530.64Dyrk1A-IN-4
CAS:Dyrk1A-IN-4, compound 48, is an oral DYRK1A/DYRK2 inhibitor with IC50s: 2 nM (DYRK1A), 6 nM (DYRK2), anticancer properties.Fórmula:C14H13F3N6Forma y color:SolidPeso molecular:322.29HNC-1664
CAS:HNC-1664 is an orally active inhibitor of RNA-dependent RNA polymerase (RdRP). It exhibits broad-spectrum antiviral activity against coronaviruses, including SARS-CoV-2 wild type and its variants (XBB.1.18, HK.3.1, BF.7.14, BA.1, HCoV-229E, HCoV-OC43), as well as arenaviruses. HNC-1664 also demonstrates anti-infective efficacy in a mouse model infected with the SARS-CoV-2 Delta variant.Fórmula:C12H13FIN3O3Forma y color:SolidPeso molecular:393.153BET/Aurora kinase-IN-1
CAS:BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.Fórmula:C25H30FN7OForma y color:SolidPeso molecular:463.55GSK3335103
CAS:GSK3335103 is a non-peptide, orally active inhibitor of αvβ6 integrin (pIC50=8), employed in the study of pulmonary fibrosis.Fórmula:C27H36FN3O4Forma y color:SolidPeso molecular:485.59Polθ-IN-7
CAS:Polθ-IN-7 (example 12) is an inhibitor of DNA polymerase θ (Polθ) with a Ki of 1.27 nM.Fórmula:C28H35F3N6O2Forma y color:SolidPeso molecular:544.612BRD4 Inhibitor-40
CAS:BRD4 Inhibitor-40 (Compound 23) functions as an inhibitor of BRD, effectively targeting BRD4-BD1, BRD4-BD2, BRD2-BD1, and BRD2-BD2, with IC50 values of 16.1, 142.18, 29.35, and 302.35 nM, respectively. It modulates the expression of c-Myc and p21, induces cell cycle arrest in the G1 phase, and inhibits Pkd1-deficient (PN) renal cystic epithelial cells. Additionally, it prevents renal cyst formation in both Madin-Darby canine kidney and embryonic kidney cyst models, and demonstrates renal cyst inhibition activity in mouse models.Fórmula:C27H32N8OForma y color:SolidPeso molecular:484.596DNA Gyrase-IN-16
CAS:DNA Gyrase-IN-16 (Compound 9) is an inhibitor of DNA gyrase, with an IC50 of 1.609 μM. It exhibits antibacterial properties, effectively inhibiting S. aureus and MRSA, with a MIC of 3.125 μM for both.
Fórmula:C17H15N3O3Forma y color:SolidPeso molecular:309.319Fradafiban
CAS:Fradafiban binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb/IIIa antagonist.Fórmula:C20H21N3O4Pureza:98%Forma y color:SolidPeso molecular:367.40Tizolemide
CAS:Tizolemide, a sulfonamide diuretic compound with alkaline properties, is cleared through the tubular transport system. It induces changes in the passive transport components across the basolateral membrane of isolated frog skin.Fórmula:C11H14ClN3O3S2Forma y color:SolidPeso molecular:335.83ROCK/HDAC-IN-1
ROCK/HDAC-IN-1 (Compound 10h) serves as an orally effective inhibitor of ROCK/HDAC. This compound suppresses ROCK1/2 (IC50: 254.9 nM, 58.18 nM) and HDAC1/2/3/6/8 (IC50: 9.09, 8.03, 6.26, 0.41, 7.69 nM). It stimulates the activation of DAMPs, notably calreticulin (CRT) exposure and HMGB1 release, suggesting its potential as an inducer of immunogenic cell death (ICD). ROCK/HDAC-IN-1 exhibits antiproliferative effects against breast cancer cells (IC50: 0.37 μM for MDA-MB-231 cells), inhibits tumor growth, activates T cells, and shows no significant toxicity.Fórmula:C19H22N4O3SForma y color:SolidPeso molecular:386.47KWR095
CAS:KWR095 is an orally active inhibitor of WRN, demonstrating an IC50 of 0.032 μM against WRN ATPase. It disrupts the double-stranded helicase activity of WRN and inhibits tumor cell proliferation, exhibiting antitumor properties.Fórmula:C33H31ClF3N9O4Forma y color:SolidPeso molecular:710.1053'-Deoxy-GTP
CAS:3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate) is an analog of GTP and serves as an RNA chain terminator, effectively inhibiting RNA synthesis. It can inhibit dengue virus DENV NS5 RdRp with an IC50 of 0.02 μM.Fórmula:C10H16N5O13P3Forma y color:SolidPeso molecular:507.181L-Tyrosyl-L-glutamic acid
CAS:L-Tyrosyl-L-glutamic acid acts as an inhibitor of the amino acid permease GAP1.Fórmula:C14H18N2O6Forma y color:SolidPeso molecular:310.3LY309887
CAS:LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (Ki: 6.5 nM). It also has antitumor activity.Fórmula:C19H23N5O6SForma y color:SolidPeso molecular:449.48CDK4/6-IN-24
CAS:CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.Fórmula:C32H41N7O3Forma y color:SolidPeso molecular:571.713MU1409
CAS:MU1409 is an MRE11 nuclease inhibitor with an IC50 of 12.1 μM. It also inhibits FEN1 and EXO1, with IC50 values of 24.2 μM and 176.4 μM, respectively. MU1409 impacts cellular DNA repair and prevents the degradation of stalled replication forks in BRCA2-deficient cells, making it a promising candidate for studying BRCA2 mutation-induced cancers.Fórmula:C20H14BrN3O3SForma y color:SolidPeso molecular:456.312TREX1-IN-4
CAS:TREX1-IN-4 (Compound 96) is an inhibitor of TREX1 and TREX2, exhibiting an IC50 of less than 0.1 μM for TREX1 and an IC50 of less than 1 μM for TREX2. It has an EC50 ranging from 0.1 to 10 μM in HCT116 cells. TREX1-IN-4 is applicable for research in the field of cancer.Fórmula:C24H19ClN6O4Forma y color:SolidPeso molecular:490.898DL-Alanosine
CAS:DL-Alanosine is an amino acid analog with antitumor activity.Fórmula:C3H7N3O4Forma y color:SolidPeso molecular:149.105Zeltociclib
CAS:Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.Fórmula:C18H20F3N4O2PForma y color:SolidPeso molecular:412.346Polθ-IN-5
CAS:Polθ-IN-5 (Compound 139) is an inhibitor of DNA polymerase theta (Polθ) that exhibits antitumor activity.Fórmula:C23H18ClF2N7O3SForma y color:SolidPeso molecular:545.95LNA-AMP
CAS:LNA-AMP is a nucleotide analog used in the synthesis of oligonucleotides.Fórmula:C11H14N5O7PForma y color:SolidPeso molecular:359.23Dyrk1A-IN-12
CAS:Dyrk1A-IN-12 (compound S43) is an inhibitor of dual specificity tyrosine phosphorylation regulated kinase 1A (Dyrk1A). It has an IC50 of 95 nM for inhibiting Dyrk1A. The compound demonstrates antiviral activity against EV-A71 (Enterovirus A71) with an EC50 of 4.4 μM, a CC50 of 12.8 μM, and a selectivity index (SI) of 2.9. Additionally, Dyrk1A-IN-12 exhibits potent inhibitory effects on the herpes simplex virus (HSV).Fórmula:C22H16FN3O2SForma y color:SolidPeso molecular:405.445SGC-CLK-1
CAS:SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Fórmula:C19H15F3N6O2Forma y color:SolidPeso molecular:416.36Cdc7-IN-19
CAS:Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].Fórmula:C19H21N5O2Forma y color:SolidPeso molecular:351.40CHK-IN-1
CAS:CHK-IN-1 is a dual inhibitor of CHK1 and CHK2 with antiproliferative activity.Fórmula:C18H19ClFN5OSPureza:>99.99%Forma y color:SolidPeso molecular:407.89CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Fórmula:C20H18N4O4Forma y color:SolidPeso molecular:378.38c-Myc inhibitor 4
Potent oral c-Myc inhibitor 4 reduces the proto-oncogene linked to tumor development.Fórmula:C26H33FN6O3Forma y color:SolidPeso molecular:496.58
